专题：2025可持续全球领导者大会江苏专场、第二届国联投资人大会 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 文/新浪财经上海站 陈秀颖 资本奔腾如潮，产业迭代如风。全球经济格局风云激荡，第二届国联投资人大会、2025可持续全球领导 者大会江苏专场，于11月6日在无锡隆重举行。大会以"'锡'引全球资本 赋能现代产业"为主题，聚焦资 本与产业的双向奔赴。 作为中国新能源领域的代表性企业，协鑫集团创始人朱共山在大会期间接受了新浪财经专访。他谈及协 鑫三十五年坚守能源主业的初心，也分享了对绿色金融、产业协同以及国际布局的深度思考。 与新材料领域的创新企业提供长期资本支持。" 朱共山认为，金融的本质是服务于产业，而绿色金融的核心，是引导资本流向可持续方向。"未来的金 融，不再只是资金的搬运工，而要成为绿色发展的加速器。"他强调，资本要有温度，金融要有方向， 只有当金融与实业同频共振，地方经济才能行稳致远。 在"十五五"周期里重构绿色信仰 三十五年如一日，专注能源的协鑫集团 "协鑫成立三十五年来，从未离开能源主航道。"朱共山的开场语，稳健而笃定。 三十五年的时间，协鑫从一家地方性企业成长为 ...

Core Viewpoint - Fumiao Technology (688350.SH) plans to invest up to $2 million to establish a wholly-owned subsidiary in Singapore to enhance its international presence and product supply capabilities in the global market [1] Group 1: Investment and Strategic Planning - The investment will utilize the company's own funds, indicating a commitment to self-financed growth [1] - The Singapore subsidiary will play a crucial role as an overseas platform, leveraging Singapore's status as an international financial and shipping hub [1] Group 2: Market Expansion and Competitiveness - The establishment of the subsidiary aims to promote multinational collaboration and expand the company's reach in the global market [1] - This move is expected to enhance the company's product advantages in international competition [1]

Core Viewpoint - The article highlights the market capitalization changes of major domestic life science instrument manufacturers in China for 2025, indicating a mixed performance with significant growth for some companies and declines for others due to policy impacts and market dynamics [1][2]. Market Capitalization Summary - The top five companies by market capitalization in 2025 are Mindray Medical, Sunny Optical, BGI Genomics, Antu Bio, and Haier Biomedical [2]. - A total of 10 companies experienced growth in market capitalization compared to 2024, with Zhongke Meiling leading at a growth rate of +130.44% [2]. - Four companies saw a decline in market capitalization, with Antu Bio experiencing the most significant drop at -26.70% [2]. Policy Impact Analysis - The medical anti-corruption and centralized procurement policies have negatively affected the revenue of several companies, leading to a 35% decrease in equipment bidding volume in tertiary hospitals [3]. - Mindray Medical, despite being an industry leader, faced a revenue growth drop from 25% to 9% due to procurement delays and budget constraints from DRG payment reforms [3]. - Antu Bio's revenue decreased by 18% in 2024 due to the impact of centralized procurement on the prices of chemical luminescence reagents [4]. Growth Drivers - Companies are shifting towards technology innovation as traditional high-margin models and bundled sales strategies become less viable under centralized procurement [5]. - Domestic microscope manufacturers have seen significant market capitalization growth, with Sunny Optical (+47.04%), Yongxin Optical (+27.11%), and Motic (+69.22%) benefiting from increased demand and technological advancements [7]. - Zhongke Meiling achieved a market share increase from 3% to 8% by overcoming technical barriers in ultra-low temperature freezing equipment [8]. International Expansion and Market Strategy - Companies are increasingly focusing on international markets to seek new growth opportunities, with Mindray Medical expanding its factory in New Jersey as part of its international strategy [8]. - BGI Genomics and Motic are also pursuing CE/FDA certifications to enter European and American markets, indicating a shift from domestic competition to global opportunities [8].